Compare IMNN & ICCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IMNN | ICCM |
|---|---|---|
| Founded | 1982 | 2006 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.9M | 8.3M |
| IPO Year | 2000 | 2013 |
| Metric | IMNN | ICCM |
|---|---|---|
| Price | $1.00 | $0.90 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $17.00 | ★ $22.67 |
| AVG Volume (30 Days) | 95.7K | ★ 150.1K |
| Earning Date | 11-12-2026 | 11-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $27.11 |
| Revenue Next Year | N/A | $104.97 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.81 | $0.13 |
| 52 Week High | $4.60 | $9.54 |
| Indicator | IMNN | ICCM |
|---|---|---|
| Relative Strength Index (RSI) | 36.60 | 19.13 |
| Support Level | N/A | $0.22 |
| Resistance Level | $1.28 | $2.50 |
| Average True Range (ATR) | 0.08 | 0.10 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 23.08 | 22.56 |
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the coding of proteins and cytokines in the treatment of solid tumors. The second modality, PlaCCine, is developed for the coding of viral antigens that can elicit an immunological response. The company's clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.